NCT00404274 - A Study Testing the Effect and Safety of Casopitant (GW679769) While Taking Warfarin in Healthy Human Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 1, 2006

Primary Completion Date

March 18, 2007

Study Completion Date

March 18, 2007

Conditions

Nausea and Vomiting, Chemotherapy-Induced

Interventions

DRUG

Casopitant (GW679769) oral tablets

Casopitant will be available in the dose strength of 20,30 or 50 mg

DRUG

Warfarin oral tablets

Warfarin will be available in the dose strength of 5 mg

Trial Locations (2)

GSK Investigational Site, Buffalo

GSK Investigational Site, Gainesville